Perrigo Company plc (BVMF:P1RG34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 7.51B -61.6% |
| Revenue (ttm) | 21.90B -3.6% |
| Net Income | -9.53B |
| EPS | -68.66 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 5.05 |
| Dividend | 4.56 (7.93%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 20 |
| Average Volume | 252 |
| Open | 56.80 |
| Previous Close | 57.50 |
| Day's Range | 56.80 - 56.80 |
| 52-Week Range | 49.50 - 133.90 |
| Beta | 0.54 |
| RSI | 47.57 |
| Earnings Date | May 6, 2026 |
About Perrigo Company
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pai... [Read more]
Financial Performance
In 2025, Perrigo Company's revenue was $4.25 billion, a decrease of -2.75% compared to the previous year's $4.37 billion. Losses were -$1.43 billion, 729.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Perrigo reports Q1 EPS 43c, consensus 31c
Reports Q1 revenue $969.2M, consensus $1.04B. “Our first quarter results reflect tangible progress as we continue to transform Perrigo (PRGO) into a more focused, disciplined, and consistent business,...
Perrigo reports Q1 EPS 43c, consensus 31c
Reports Q1 revenue $969.2M, consensus $1.04B. “Our first quarter results reflect tangible progress as we continue to transform Perrigo (PRGO) into a more focused, disciplined, and consistent business,...
Perrigo Company Earnings Call Transcript: Q1 2026
First quarter 2026 saw sales and margins pressured by weak cough/cold demand and retailer destocking, but market share gains and cost savings supported results. Full-year guidance is reaffirmed, with improvement expected in the second half as headwinds ease.
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
Mitigating category headwinds with market share gains through implementation of Three‑S plan. Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum i...
Perrigo Completes Divestiture of Dermacosmetics Business
Advances key Three-S plan pillar, streamlining portfolio Upfront net proceeds of approximately €306 million will enable debt reduction DUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE:...
Perrigo Announces Quarterly Dividend
DUBLIN, April 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend o...
Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026
DUBLIN, April 22, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that it plans to issue its first quarter 2026 financial results...
Perrigo rumor highlighted in Betaville blog
A rumor regarding Perrigo (PRGO) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly.
Perrigo shares up 5% after rumor highlighted in M&A blog
09:55 EDT Perrigo (PRGO) shares up 5% after rumor highlighted in M&A blog
Perrigo Company Transcript: UBS Global Consumer and Retail Conference
A leading OTC health provider reported strong market share gains, significant cost savings, and a focused strategy on innovation, portfolio simplification, and disciplined capital allocation. Despite market softness, stabilization is expected in H2 2026, with long-term growth driven by brand building and geographic expansion.
5 Small Caps With Yields Up To 11% That Punch Like Heavyweights
What's better than getting to buy 6.6%-11% yields at discounted prices?
Perrigo to Present at the UBS Global Consumer and Retail Conference
DUBLIN, Ireland, March 3, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that President and CEO Patrick Lockwood-Taylor is sched...
Perrigo price target lowered to $15 from $18 at JPMorgan
JPMorgan lowered the firm’s price target on Perrigo (PRGO) to $15 from $18 and keeps a Neutral rating on the shares.
Perrigo price target lowered to $17 from $20 at Canaccord
Canaccord analyst Susan Anderson lowered the firm’s price target on Perrigo (PRGO) to $17 from $20 and keeps a Buy rating on the shares. The firm said Management noted they…
Perrigo Company Earnings Call Transcript: Q4 2025
Delivered strong share gains and EPS growth in 2025 despite market softness, with 2026 set as a transition year facing temporary headwinds but expecting improvement in the second half. Operational enhancements and portfolio streamlining continue, with a focus on innovation and cost savings.
Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations
Delivered FY2025 Adj. EPS at the Midpoint of Updated Outlook Range Advanced '3-S Plan' with Perrigo Store Brand OTC and Key Brands Gaining Share 1,2 in 2025, Despite Soft Category Consumption Launchin...
Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
DUBLIN, Feb. 13, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that it plans to issue its fourth quarter and fiscal year 2025 f...
Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO.
SAN DIEGO--(BUSINESS WIRE)---- $PRGO #Health--Robbins LLP: Company: Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally. What ...
Perrigo price target lowered to $18 from $20 at JPMorgan
JPMorgan lowered the firm’s price target on Perrigo (PRGO) to $18 from $20 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first on…
PERRIGO COMPANY PLC (NYSE: PRGO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Perrigo Company plc Investors of Upcoming Deadline
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Perrigo Company plc (NYSE: PRGO)? Did you purchase your shares between February 27, 2023 and Novem...
PERRIGO COMPANY PLC (NYSE: PRGO) INVESTOR ALERT Investors With Large Losses in Perrigo Company plc Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Perrigo to Attend Morgan Stanley Global Consumer & Retail Conference
DUBLIN , Nov. 18, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo ...
Perrigo price target lowered to $20 from $40 at Canaccord
Canaccord lowered the firm’s price target on Perrigo (PRGO) to $20 from $40 and keeps a Buy rating on the shares. The firm noted Q3 was a beat but sales…
Perrigo downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Perrigo (PRGO) to Neutral from Overweight with a price target of $20, down from $32, post the Q3 report. The firm sees increased uncertainty for the business in…
